01—Abstract
Summary
Summary of the 10-Q filed July 29, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation's second-quarter 2026 results show net sales of $920.6 milliona for the three months ended June 30, 2026, up from $865.4 million, and net sales of $1,807.5 million for the six months, up from $1,679.7 million.
Reported net income attributable to IDEX was $143.4 millionb for the quarter, versus $131.6 million a year earlier, and diluted EPS was $1.93 versus $1.74. The company attributes the increase mainly to organic sales growth of 5% in both periods, driven by higher volumes in the Health & Science Technologies segment, along with favorable foreign currency and acquisition contributions. Adjusted diluted EPS attributable to IDEX was $2.32 for the quarter, up from $2.07.
IEEPA tariff refunds were a significant factor this quarter. The company collected substantially all anticipated refunds in Q2 2026, which reduced cost of sales by $22.0 millionc, partly offset by a $14.7 million reduction in net sales from expected customer rebates. Management says the net impact contributed an $0.08 benefit to EPS.
Gross margin rose to 46.3% for the quarter from 45.3%, and operating income increased to $199.9 milliond from $187.9 million. Balance sheet and cash flow remained solid. Cash and cash equivalents were $621.3 million, borrowings were $1,866.9 million in total, and the Revolving Facility had $529.6 million of net availability.
Operating cash flow for the six months was $303.7 million, and free cash flow was $263.0 million. The company returned $77.1 million through share repurchases and $53.9 million through dividends in the quarter, and $774.7 million of repurchase authorization remained at June 30, 2026.
02—Key points
Key Highlights
- Net sales rose to $920.6 million in Q2 2026 from $865.4 million, with organic sales up 5%, driven mainly by higher volumes in the HST segment.
- Diluted EPS attributable to IDEX was $1.93 for Q2 2026 versus $1.74, and adjusted diluted EPS was $2.32 versus $2.07.
- IEEPA tariff refunds reduced cost of sales by $22.0 million and reduced net sales by $14.7 million through expected customer rebates; management cites a $0.08 EPS benefit.
- Gross margin was 46.3% in Q2 2026 versus 45.3% a year earlier, and operating income increased to $199.9 million from $187.9 million.
- Operating cash flow for the six months was $303.7 million, versus $267.4 million, and free cash flow was $263.0 million versus $238.3 million.
- The company repurchased $151.3 million of stock in the first six months and had $774.7 million of authorization remaining at June 30, 2026.
- Restructuring expenses and asset impairments were $10.2 million for the six months, including $4.8 million of asset impairments in the FMT segment; the company reported covenant compliance with an interest coverage ratio of 14.17 to 1.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2026, Idex kept $0.16.
- Revenue$920.6M100.0%
- Cost of revenue−$493.8M53.6%
- Gross profit$426.8M46.4%
- Operating costs−$226.9M24.6%
- Operating income$199.9M21.7%
- Interest, other & tax−$56.5M6.1%
- Net income$143.4M15.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed July 29, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $920.60M$865.40M | +6.4% |
| Cost of Revenue | $493.80M$473.20M | +4.4% |
| Gross Profit | $426.80M$392.20M | +8.8% |
| SG&A Expenses | $224.10M$203.60M | +10.1% |
| Operating Income | $199.90M$187.90M | +6.4% |
| Net Income | $143.40M$131.60M | +9.0% |
| EPS (Basic) | $1.94$1.74 | +11.5% |
| EPS (Diluted) | $1.93$1.74 | +10.9% |
| Shares Outstanding (Basic) | 74.00M75.50M | −2.0% |
| Shares Outstanding (Diluted) | 74.20M75.50M | −1.7% |
05—Questions
Frequently Asked Questions
What drove the increase in IDEX's second-quarter 2026 sales and earnings?
Net sales increased 6% to $920.6 million, with organic sales up 5%, primarily from higher volumes in the Health & Science Technologies segment, including AI-driven demand for data center power and semiconductor markets. Favorable foreign currency and acquisitions also contributed. Diluted EPS rose to $1.93 from $1.74.
How did the IEEPA tariff refunds affect results?
The company collected substantially all anticipated IEEPA tariff refunds in Q2 2026, reducing cost of sales by $22.0 million, while expected customer rebates reduced net sales by $14.7 million. Management states the net impact added an $0.08 benefit to EPS and more than offset a challenging prior-year price/cost comparison.
How is IDEX's liquidity and balance sheet position?
At June 30, 2026, cash and cash equivalents were $621.3 million and total borrowings were $1,866.9 million. The Revolving Facility had $529.6 million of net availability, and working capital was $1,191.7 million. Management believes current cash, operating cash flow and the Revolving Facility will meet its cash requirements for the foreseeable future.
How much capital did IDEX return to shareholders?
In Q2 2026, the company returned $77.1 million through share repurchases and $53.9 million through dividends. For the six months, it paid $153.4 million for repurchases and $106.7 million in dividends. Authorization remaining at June 30, 2026 was $774.7 million, and the company repurchased an additional $21.7 million of shares after quarter-end.
Were there any notable restructuring or impairment charges?
Restructuring expenses and asset impairments were $2.8 million for Q2 2026 and $10.2 million for the six months, mainly severance costs. The six-month figure includes $4.8 million of asset impairments in the FMT segment. Accelerated depreciation tied to the anticipated closure of an HST facility was also recorded.
06—Continue